Most research on the P450 (CYP) system in teleosts has been done on environmental 20 factors that influence their induction. Less is known about CYP metabolism of aquaculture 21 antibiotics. This paper outlines the impact of aquaculture antimicrobials on the piscine 22 CYP system, with particular regard to interactions with tetracyclines, fluorokinolones, 23 sulfonamides, berberine and chloramphenicol, as paradigms for current, potential and 24 discontinued piscine antimicrobial drugs. It gives an overview of literature reports and 25 advances in the field of biological significance of the CYP in fish. Emphasis has been 26 placed on highlighting the most significant isoforms for biotransformation of drugs, and 27 their drug response mechanisms. The challenge is to elucidate the differences in responses 28 of CYP enzymes in different species to antimicrobial treatment since they may have 29 relevance for the use of antimicrobials in aquaculture, especially since drug interactions 30 with the fish CYP may alter their distribution, metabolism, and elimination. They can 31 impact the metabolism of other drugs metabolized by the same system with an effect on 32
Introduction 37 38
In farming of aquatic organisms, medications are needed to maintain animal health and 39 manage fish populations. However, the development of therapeutic agents for the treatment 40 of fish diseases involves long and complex processes. When compared with mammals, fish 41 have some differences in pharmacokinetics that need to be considered. For example, 42 differences in bioavailability of tetracycline, quinolones, and beta-lactam antimicrobials 43 have been documented (Storey 2005) . Oxytetracycline and amoxicillin are not well 44 absorbed from the intestines of fish. The doses of these antimicrobials are generally 2 to 5 45 times that needed to produce therapeutic systemic concentrations in mammalian species 46 (Burka et al. 1997) . Also, for several antimicrobials, the cations present in seawater inhibit 47 their absorption from the intestine, while their pharmacokinetics is affected by water 48 temperature as well (Burka et al. 1997; Storey 2005) . As in other animals, most 49 pharmaceuticals are metabolized by CYP enzymes in fish, which makes them of critical 50 importance both for detoxification or formation of toxic metabolites. 51
Drugs are usually lipophilic, which allows them to enter their site of action of target 52 organs or tissues via cell membranes and exert their effect. As lipid soluble compounds, 53 they are difficult to eliminate from the body. Metabolism, or biotransformation of these 54 compounds into more polar, inactive metabolites, is generally an enzymatic process 55 are extraordinary diverse, and inhabit virtually every niche within the world's fresh and 108 marine waters (Stegeman 1989) . They are also a direct food source for humans as well as 109 conveyors of toxic chemicals to human beings (Sen & Arinc 1998) . 110 6 Initially it was thought that fish lacked CYP-linked monooxygenases, but studies 111 carried out in the late 1960s by Buhler and Rasmusson (1968) and Dewaide and Henderson 112 (1968) showed that these enzymes were present in the livers of rainbow trout and other 113 fish. Enzyme activities of fish hepatic microsomes were generally lower than in mammals 114 and many fish CYPs had temperature optima of about 25ºC, explaining why they were not 115 detected in the earlier studies where incubations at higher temperatures were employed. 116
Subsequently, as observed in mammals, multiple CYP forms were discovered in fish, 117 predominately localized in the liver, but also found in lower concentrations in other tissues, 118 like kidney, gut, gall bladder, gonads, nervous tissue, endocrine cells, gills etc. (Andersson 119 & Förlin 1992; Buhler 1995; Sarasquete & Segner 2000) . 120
Fish hepatic microsomes exhibit typical reduced CO absorption spectra with a peak 121 near 450 nm, and electron paramagnetic resonance characteristics with low-spin g values 122 near 2.41, 2.25, and 1.91 typical for CYPs. Specific contents of CYPs in fish hepatic 123 microsomes cluster between 0.2 and 0.5 nmol/mg. They range from less than 0.1 nmol/mg 124 to nearly 2.0 nmol/mg microsomal protein. Such differences in content can occur within a 125 single species, depending on strain, sex or chemical treatment (Andersson & Förlin 1992). 126
Fish hepatic microsomes catalyze epoxidation, hydroxylation, dealkylation and oxidation 127 reactions ascribed to CYP in other systems (Gillam 2007; Gillam & Hunter 2007) . 128
Substrates metabolized include many that are used to characterize CYPs in mammals, but 129 activities found in teleosts might be catalyzed by CYP forms largely unrelated to the 130 catalyst for the same activity in mammalian systems. Conversely, CYP forms that are 131 structural homologues in teleosts and mammals could have different activities (Stegeman 132 1993) . One of the major differences between mammalian and fish CYPs is that some fish 133 species have much higher constitutive levels of aryl hydrocarbon hydroxylase (AHH) than 134 mammalian counterparts (Lee et al. 1992). CYP1B1 was found to be the major isoform 135 7 involved in AHH activity in human lymphocytes (Toide et al. 2003 ). Goksøyr et al. (1987) 136 described certain characteristic features of the fish xenobiotic metabolizing systems: 137 generally lower specific activities compared to mammals, but high capability to activate 138 procarcinogens to reactive intermediates; high responsiveness of monooxygenase activities 139 to the polycyclic aromatic hydrocarbons (PAH) class of inducers (3-MC, beta-140 Naphthoflavone BNF, BP, etc.), but an apparent refractiveness to induction by the PB. In 141 fish, CYPs have mostly been studied as catalysts for bioactivation of carcinogens and 142 biomarkers of environmental contamination (Råbergh et al. 2000) . 143
As in the mammalian system, multiple forms of CYPs belonging to the families of 144 The most common route of delivery of these legal antibiotics to fish occurs through mixing 292 with specially formulated feed. In the USA there are currently only three FDA-approved 293 and available antibiotic drugs for use in fish. They are oxytetracycline, ormetoprim and 294 sulfadimethoxine, and florfenicol. FDA will sometimes allow veterinarians to prescribe the 295 use of medicated feed for fish species other than those listed on the label. For example, 296 oxytetracycline medicated feed approved for use in catfish, may be prescribed off label for 297 hybrid striped bass by a licensed veterinarian (Durborow & Francis-Floyd 1996) . acted as a potent inhibitor of crucian carp CYP1A, reducing not only CYP1A mRNA 422 expression in a dose-dependent manner, but also directly inhibiting this enzyme 423 competitively. Also, high berberine doses inhibited CYP3A through the downregulation of 424 its expression at the both mRNA and protein level. The authors compared the identity of 425 this crucian carp CYP1A isoform with those of human at the amino acid level and found 426 that it had a stronger identity with human CYP1A2 than CYP1A1. Hence, the mechanisms 427 underlying the effects of berberine on crucian carp CYP1A isoform and human CYP1A 428 expressions may be quite different. 429 Chloramphenicol (CP), a broad spectrum antibiotic, has previously been used for 430 treatment of fish bacterial diseases, particularly furunculosis and diseases caused by 431 pseudomonads (Snieszko 1954) . In trout liver cells the biotransformation of labeled CP, 432 CP-glucuronide, was found to be the major metabolite, along with the CP-base, CP-alcohol 433 19 and CP-oxamic acid, while the metabolic rate of the 3H-CP reached 0.2 nmol/hr/106 trout 434 hepatocytes (Cravedi & Baradat 1991) . Snegaroff et al. (1989) The variable effects in the response among different fish species to antimicrobial drugs is a 468 valid reason to critically use assays developed for mammals for evaluating drug response 469 in various fishes. Also, the use of CYP antibodies across phyla can be of value if caution is 470 exercised in the interpretation. Substrates developed for use in mammalian systems have 471 been assayed in fish, and are useful for CYP-mediated functional comparison between 472 mammalian and fish species. Standardized protocols for drug impact on fish CYPs will 473 facilitate those studies and standards will be necessary for the future application on 474
teleosts. 475
Since the metabolism of aquaculture antimicrobials by the CYP enzymes could also 476 determine the metabolism of other xenobiotics and endogenous compounds, along with 477 persistence of residues and the length of the withdrawal period before fish being apt for 478 human consumption, and taking into consideration other challenges and concerns 479 regarding drug approval/administration/dosing/metabolism, impact of antimicrobial drugs 480 on piscine CYPs requires further in-depth studies, equal to their mammalian counterparts. 
